MedWatch

Danish Business Authority's decision causes Lundbeck to downgrade guidance

Lundbeck adjusts its EBIT guidance after the Danish Business Authority ordered a reassessment of the impairment.

Photo: Martin Lehmann/Ritzau Scanpix

Now, the Danish pharmaceutical firm Lundbeck's operational guidance for 2020 is at DKK 1.7-1.9bn (USD 275.6m-308.0m), down from DKK 2.0-2.2n. Lundbeck, however, states that its guidance for earnings before interest, taxes, depreciations and amortizations and core EBIT remain unchanged, according to a stock exchange announcement on Friday afternoon.

This comes after the Danish Business Authority having decided that Lundbeck has to have a reassessment of its impairment for 2017. This includes back-tracking a writedown for the drug Rexulti, according to Lundbeck.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles